Resveratrol (3,4’,5-trihydroxy-trans-stilbene) or caffeic acid phenethyl ester supplementation prevents premature ovarian insufficiency due to chemotherapy

Suat S. Ersahin

Department of Obstetrics and Gynecology, Altinbas University, Istanbul, Turkey

Submitted: 7 May 2020
Accepted: 13 August 2020

Arch Med Sci
DOI: https://doi.org/10.5114/aoms.2020.100668
Copyright © 2020 Termedia & Banach

Abstract

Introduction: This study was planned to investigate the protective effect of resveratrol (RSV), caffeic acid phenethyl ester (CAPE), and coenzyme Q10 (CoQ10) on chemotherapy-induced premature ovarian insufficiency (POI).

Material and methods: Twenty-eight female rats were divided into four groups with 7 rats in each group. The groups consisted of a vehicle-treated control group (group 1), rats treated with chemotherapy followed by intraperitoneal RSV injection (group 2) or rats treated with chemotherapy followed by CoQ10 (group 3), or rats treated with chemotherapy followed by intraperitoneal CAPE injection (group 4). Cisplatin was administered intraperitoneally once daily at doses of 2.0 mg/kg for 10 days. Rats in groups 2, 3, and 4 were given RSV (100 mg/kg, i.p.), CoQ10 (20 mg/kg, oral), and CAPE (10 mg/kg, i.p.) respectively. Five animals in the sham group underwent laparotomy for ovarian weight measurements on the first day of cisplatin injection. Animals in the treatment and control groups were sacrificed two weeks later, and their ovaries were excised for histopathological analysis. Serum levels of anti-Mullerian hormone (AMH) were also analyzed.

Results: Rats in groups 2 and 4 showed vaginal smears under estrogenic effect. At the end of the second week, the total body weight and ovarian weight of the animals in group 1 increased. Significantly higher mean follicle count was detected in groups 2 and group 4 compared to group 3. The ovaries of the rats in the control group showed follicles in all stages of development. While the ovaries of the rats in the RSV or CAPE showed significantly decreased numbers of primordial follicles they showed increased numbers of early growing follicles.

Conclusions: Both RSV and CAPE administration might improve follicle survival and AMH production in rats with chemotherapy-induced POI but further research is necessary.

Key words: resveratrol, CAPE, CoQ10, premature ovarian failure, oocyte preservation.

Introduction

One of the most important concerns of infertility practice is chemotherapy-induced diminished ovarian reserve [1]. Hence, protection of the ovarian follicle loss in women with different types of cancer has gained increasing attention [2, 3]. Use of gonadotropin releasing hormone analogs, cryopreservation of oocytes, and cryopreservation of ovarian cortical tissues are commonly considered strategies for preservation of ovarian...
Coenzyme Q10, a fat-soluble component of near mitochondrial membrane, is located in the inner mitochondrial electron transport chain and has antioxidant properties [17]. It has been reported that CoQ10 supplementation causes a significant increase of CoQ10 levels in ovaries [18]. Ozcan et al. [19] reported that ovarian reserve was preserved with 150 mg/kg/day CoQ10 application in a chemotherapy-induced ovarian injury model. In connection with this, by preventing cell membrane peroxidation and free radical oxidation CoQ10 may be involved in inhibition of follicle depletion due to chemotherapy. However, there are no clear data on whether these three molecules have a follicle protective effect on the POI model. In this study, RSV, CAPE and CoQ10, which have been scientifically proven to have strong antioxidant, anti-apoptotic and cell survival effects [1–3], were used to investigate the possible protective role of these molecules on ovarian follicle depletion in animals with cisplatin-induced premature ovarian insufficiency (POI). The aim of this study was to investigate the possible follicle-protective effect of RSV, CAPE, or CoQ10 on an experimentally induced POI model.

Material and methods
Grouping of animals
In the current study, the care of the rats and all surgical procedures to be performed were planned in accordance with Guide for the Care and use of Laboratory Animals. The study was carried out in Altinbas University Faculty of Medicine. Local ethical approval of this study was obtained from Altinbas University Hospital. Twenty-eight female Wistar Albino strains weighing 200–350 g were kept under standard environmental, heat, housing and feeding conditions. They were equally divided into four groups with 7 rats in each group: the groups consisted of a vehicle-treated control group (group 1), or chemotherapy-treated rats received resveratrol injection (group 2), or chemotherapy-treated rats received oral CoQ10 (group 3), or chemotherapy-treated rats received CAPE injection (group 4). A sham group (placebo surgery) consisting of five animals was created to measure baseline ovarian weights. On the first day of cisplatin injection to other groups, animals in the sham group underwent laparotomy and their ovaries were surgically removed to calculate the ovarian weights. Unlike other groups, animals in the sham group were not exposed to cisplatin, so the POI model was not applied in animals in this group. In addition, the animals in this group underwent laparotomy without any follicle-sparing treatment and the weights of their ovaries were measured.

Creating a rat model of premature ovarian insufficiency with cisplatin
Rats were chosen to create the POI model because it is easily accessible and their ovarian
Resveratrol (3,4ʹ,5-trihydroxy-trans-stilbene) or caffeic acid phenethyl ester supplementation prevents premature ovarian insufficiency due to chemotherapy

**Table I. Comparison of the groups according to measured parameters**

| Groups | Total follicle count | AMH [ng/ml] | Ovarian* weight [g] | Body weight [g] |
|--------|---------------------|-------------|---------------------|-----------------|
| I: Control (n = 7) | 18.4 ±0.13 | 5.35 ±6.06 | 86.1 ±0.29 | 294.2 ±13.2 |
| II: RSV (n = 7) | 16.6 ±1.22 | 4.96 ±1.41 | 78.1 ±9.18 | 286.4 ±1.02 |
| III: CoQ10 (n = 7) | 8.48 ±1.45 | 3.52 ±1.44 | 67.1 ±50.9 | 220.1 ±9.01 |
| IV: CAPE (n = 7) | 13.7 ±3.22 | 5.10 ±2.70 | 77.1 ±43.1 | 278.5 ±6.45 |
| Sham (n = 5) | | 84.5 ±12.2 |

*The ovarian weights of the animals in the sham group were used for comparison with the ovarian weights of the other animals in the treatment group. RSV – resveratrol, CoQ10 – coenzyme Q10, CAPE – caffeic acid phenethyl ester.*
Results

Rats given CAPE or RSV showed vaginal smears with superficial cells showing an estrogeneic effect. H-score evaluation of the ovaries demonstrated a higher mean follicle count in group 2 and group 4 compared to group 3. The ovarian cross-sectional area was not significantly different between groups 1, 2, and 4 in terms of the number of individual follicle types. The total follicle number of animals in the control group was approximately 2.5 times that of animals in group 3 (18.4 ±0.13 vs. 8.48 ±1.45, p < 0.001). When the control group and the RSV group were compared, the total follicle numbers were similar (18.4 ±0.13 vs. 16.6 ±1.22, p < 0.41). The total number of follicles in the control group was higher than CAPE, but the difference was not significant (18.4 ±0.13 vs. 13.7 ±3.22, p < 0.57). However, rats in group 3 had a lower total number of ovarian follicles than those in groups 2 (8.48 ±1.45 vs. 16.6 ±1.22, p < 0.05) and 4 (8.48 ±1.45 vs. 13.7 ±3.22, p < 0.05).

Groups 2 (4.96 ±1.41 vs. 3.52 ±1.44 ng/ml, p < 0.05) and 4 (5.10 ±2.70 vs. 3.52 ±1.44 ng/ml, p < 0.05) had significantly higher serum AMH levels than in group 3. Compared to control group rats, the RSV or CAPE group rats showed an insignificant decrease in serum levels of AMH. Compared to the control group, AMH level was significantly lower in rats given CoQ10 (5.35 ±6.06 ng/ml vs. 3.52 ±1.44 ng/ml, p < 0.03). Increases in total body weight and ovarian weight were observed at the end of the second week in group 1 animals. The weight of the animals in the control group at the end of the 2nd week was higher than that of the animals in the other three groups. However, only the difference between animals in the CoQ10 group and controls was significant (294.2 ±13.2 vs. 220.1 ±9.01, p < 0.02). The weight differences of animals given CAPE or RSV and animals in the control group did not reach statistical significance. Compared to other groups, significant weight loss was detected in animals given CoQ10. Animals in the RSV or CAPE groups showed insignificant weight loss. While two rats in the CoQ10 group, died none of the rats in the RSV or CAPE group died (Table I).

Ovarian weights of sham and control groups were found to be similar on the 15th day. Ovarian weights of the animals in the CoQ10 group were significantly lower compared to both sham and control groups. The ovarian weights of the rats in the RSV and CAPE groups were lower compared to the control and sham groups, but the difference was not significant. Ovarian weights of the animals in the RSV and CAPE groups were higher than in the CoQ10 group, but the differences did not reach statistical significance. The ovaries of the rats in the control group showed follicles in all stages of development. The ovaries of the rats in the CoQ10 group showed increased numbers of primary follicles at day 15. Other stages of follicle significantly decreased in rats that were given CoQ10. While the ovaries of the rats in the RSV or CAPE group showed significantly decreased numbers of primordial follicles they showed increased numbers of early growing follicles at day 15. They showed increased numbers of primary and antral follicles. While the number of somatic cells decreased in the ovarian tissue in rats given CoQ10, there was a significant increase in inflammatory cells. Conversely, both somatic and inflammatory cell characteristics of animals given CAPE or RSV were similar to the control group.

Discussion

Chemotherapeutic agents damage the developing follicles in the ovaries in different ways. Oocyte and granulosa cells are vulnerable to damage caused by cisplatin. Some chemotherapeutics cause follicle death in the ovaries, while others block cell division steps. The ovaries activate some natural protective mechanisms to protect against the toxic effects of drugs. The regulation of apoptosis comes first among these mechanisms. A study conducted on xenograft models clearly demonstrated that chemotherapy-induced follicle death in the human ovary occurs via an apoptotic mechanism [25]. Chemotherapeutic agents reduce the ovarian reserve by damaging the DNA of developing follicles. Follicle cells try to prevent this damage by using their DNA repair enzymes [26]. In addition, chemotherapeutics reduce blood flow by damaging vascular and stromal cells in the ovary and preventing oxygenation, leading to the death of follicles. Insufficient oxygenation can also increase the production of reactive oxygen species (ROS), leading to follicle death. The ovarian follicles make efforts to prevent the harmful effect of chemotherapeutics by increasing neovascularization. A study by Soliemani et al. showed an inverse association between ovarian vascular structures and primordial follicle apoptosis [27]. Oocytes with sufficient DNA repair ability and antioxidant capacity may survive this gonadotoxic stress while others with a less efficient repair mechanism and antioxidant enzymes may be lost as a result of severe DNA damage triggering apoptotic death pathways. To offset these risks, women can be offered several options for fertility preservation, including cryopreservation of oocyte, embryo or ovarian tissue. If the patient does not accept fertility preservation methods, it may be necessary to use some medications or supplements to prevent follicle loss due to chemotherapy. Resveratrol and CAPE are two different antioxidant supplements that have recently been
used to prevent chemo-induced ovarian damage. Although the oocyte protective mechanism of action of these two molecules is not known exactly, some mechanisms are explained in experimental models. In this study, we do not know precisely the oocyte-protecting mechanism of action of RSV or CAPE since we only evaluate ovarian reserve over follicle count and AMH values. For this reason, our comments may be somewhat speculative.

In this preliminary and experimental study we found that CAPE therapy reduced chemotherapy-induced follicle loss. We do not clearly know how CAPE prevents chemotherapy-induced ovarian damage. Our comments on the chemopreventive effect of CAPE are somewhat speculative, but are based on our laboratory and clinical observations on animals. The findings that support the positive effects of CAPE are that the ovaries of the animals in the CAPE group contain sufficient early growing follicles, the decrease in serum AMH levels is insignificant, and the weight lost by the animals is similar to the control group. Apoptosis induction is one of the mechanisms in which chemotherapeutics show their toxic effects on ovaries. Preserved follicle count and AMH levels in rats that were given CAPE may be due to antiapoptotic or cell cycle regulatory actions of CAPE or its metabolites. Although we did not examine apoptotic changes in the ovary in our study, it is a known fact that CAPE stimulates cell cycle arrest in cancer cells [28, 29]. Chemotherapeutics can lead to the emergence of free oxygen radicals and exert their toxic effects on the oocytes. Since CAPE is one of the strongest molecules with an antioxidant effect, it can prevent follicle loss by reducing oxidant damage due to chemotherapy [30]. More comprehensive studies are needed to clarify all these mechanisms that we believe to be related to the use of CAPE.

The reason for the high number of follicles detected in animals receiving RSV or CAPE may be due to the positive effects of these two molecules on cell life. It has been reported that RSV or CAPE interacts with a variety of molecular targets associated with cell cycle survival pathways [31–33]. It has been reported that RSV inhibits pro-inflammatory enzyme expression, and reduces nuclear factor-κB activation and cytokine release. Treatment with resveratrol activates multiple intracellular molecules involved in cell survival and programmed cell death [34]. RSV protects the patient’s metabolic status by preventing insulin resistance and contributes to the individual’s fight against the harmful effects of chemotherapeutics [35]. The follicle count and AMH levels of animals on CoQ10 were found to be decreased. Despite its antioxidant effect, CoQ10 did not prevent follicle loss due to chemotherapy. This may be due to the fact that CoQ10 cannot be easily diffused into the oocyte. Because chemotherapy disturbs the mitochondrial function of the oocyte CoQ10 may be ineffective for restoration of the follicle. As CoQ10 is fat soluble and is found in tissues with high energy demands [36], restoration of dying cells due to chemotherapy may not be possible [37]. In addition to the increase in follicle loss in animals given CoQ10, weight loss was also greater than in other groups. The reason for these negative effects may be related to the dose of CoQ10 used or the administration route. The dose of 20 mg/kg/day used in this study may not be sufficient for a follicle protective effect.

In accordance with this opinion, a previous study reported that when given at a dose of 150 mg/kg, CoQ10 alleviates ovarian reserve reduction due to chemotherapy [19]. However, since the best absorption form of CoQ10 is provided orally, we think that the route of use does not play a role in these negative effects. For all these reasons, studies applying CoQ10 in different doses and in different ways are required.

Another possible cause of follicle preserving effects of RSV or CAPE may be due to regulatory function of these molecules in ROS generation during chemotherapy [38]. Both molecules can also exert their cell protecting function at the level of the oocyte or granulosa cell mitochondrial membrane. A supportive, apoptotic pathway located in the mitochondria has been reported to be responsible for cancer cell death [39, 40]. By inhibiting apoptosis, either RSV or CAPE might protect the oocyte or granulosa against cell death in animals with cisplatin-induced POI. The oocyte-protecting effect of RSV could also be derived from its sulfated metabolites, which have demonstrated more potent activity than RSV [14]. The generation of ROS during chemotherapy plays a pivotal role during apoptotic cell death. By decreasing glutathione and superoxide dismutase levels ROS lead to apoptotic cell loss. Therefore, antioxidant action of RSV can inhibit ROS-mediated cell death and may allow survival of the oocyte [41, 42]. Furthermore, stimulation of glutathione S-transferase (GST) with RSV may be considered a potential strategy for POI prevention in POI subjects due to chemotherapy. Glutathione S-transferase may protect against exposure to chemotherapy-induced oxidative stress [43–45]. Supporting this, both the expression and catalytic activity of GST were restored with low dose RSV supplementation [40]. Given the relation between increased GST activity and reduced cancer risk [41], stimulation of this enzyme could be a significant mechanism by which resveratrol protects the oocyte from harmful effects of anti-cancer drugs.
This experimental study has its strengths and weaknesses. Successful creation of the POI model in rats makes the study privileged, because many experimental POI models do not turn out as desired, and most animals die. On the other hand, since we evaluated both the number of follicles and AMH levels in our study, we were able to make stronger comments about the effect of these three molecules on the ovarian reserve. Moreover, the combination of three powerful antioxidant molecules enabled us to obtain strong data on the prevention of chemotherapy-induced ovarian damage. In addition to all these positive effects, our study also has limitations. The low number of animals in the experimental groups is the basic handicap. Also, giving RSV, CAPE, and CoQ10 as a single dose in the experimental groups weakens the study. The use of these three substances in different doses and in different ways of application could make our results more objective.

In conclusion, while RSV or CAPE administration does not prevent primordial follicle loss, they preserve both primary and antral follicles in a cisplatin-induced POI model. Both molecules may be used as an effective oocyte preservation method particularly among young cancer patients undergoing chemotherapy. Although the mechanisms of action are unclear, their antioxidant and anti-apoptotic effects may ameliorate harmful effects of chemotherapy agents and preserve ovarian reserve. Taken together, both CAPE and RSV supplementation might be considered as an oocyte preserving strategy in young cancer patients desiring to preserve their fertility potential. However, in order to establish a clear conclusion, more research is still necessary in this area.

Conflict of interest
The author declares no conflict of interest.

References
1. Banu SK, Stanley JA, Sivakumar KK, Arosh JA, Burghardt RC. Resveratrol protects the ovariay against chromiuom-toxicity by enhancing endogenous antioxidant enzymes and inhibiting metabolic clearance of estradiol. Toxicol Appl Pharmacol 2016; 303: 63-78.
2. Jiang Y, Zhang Z, Cha L, et al. Resveratrol plays a protective role against premature ovarian failure and prompts female germine stem cell survival. Int J Mol Sci 2019; 20: 3605.
3. Said RS, El-Demerdash E, Nada AS, Kamal MM. Resveratrol inhibits inflammatory signaling implicated in optimizing radiation-induced premature ovarian failure through antagonistic crosstalk between silencing information regulator 1 (SIRT1) and poly(ADP-ribose) polymerase 1 (PARP-1). Biochem Pharmacol 2016; 103: 140-50.
4. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018; 36: 1994-2001.
5. Spears N, Lopes E, Stefandsottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update 2019; 25: 673-93.
6. Sinha D, Biswas J, Sung B, Agarwal BB, Bishayee A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Current Drug Targets 2012; 13: 1799-819.
7. Desai AG, Qazi GN, Ganju RK, et al. Medicinal plants and cancer chemoprevention. Curr Drug Metab 2008; 9: 581-91.
8. Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 2011; 1215: 1-8.
9. Kulkarni SS, Cantó C. The molecular targets of resveratrol. Biochim Biophys Acta 2015; 1852: 1114-23.
10. Bitterman JL, Chung JH. Metabolic effects of resveratrol: addressing the controversies. Cell Mol Life Sci 2015; 72: 1473-88.
11. Zordoky BNM, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta 2015; 1852: 1155-77.
12. Fremont L. Biological effects of resveratrol. Life Sci 2000; 66: 663-73.
13. Hascalik S, Celik Q, Turkoz Y, et al. Resveratrol, a red wine constituent polyphenol, protects from ischemia-reperfusion damage of the ovaries. Gynecol Obstet Invest 2004; 57: 218-23.
14. Aires V, Limagne E, Cotte AK, Latruffe N, Ghiringhelli F, Delmas D. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res 2013; 57: 1170-81.
15. Celik Q, Turkoz Y, Hascalik S, et al. The protective effect of caffeic acid phenethyl ester on ischemia-reperfusion injury in rat ovary. Eur J Obstet Gynecol Reprod Biol 2004; 117: 183-8.
16. Grunberger D, Banerjee R, Eisinger K, et al. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Experientia 1988; 44: 230-2.
17. Mansfield KD, Guzy RD, Pan Y, et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic Hif-alpha activation. Cell Metab 2005; 1: 393-9.
18. Bentinger M, Tekle M, Brismar K, Chojnacki T, Szwijewska E, Dallner G. Stimulation of coenzyme Q synthesis. Biofactors 2008; 32: 99-111.
19. Ozcan P, Fıçıcıoğlu C, Kızılkałe O, et al. Can coenzyme Q10 supplementation protect the ovarian reserve against oxidative damage? J Assist Reprod Genet 2016; 33: 1223-30.
20. Jiang H, Lee OH, Lee Y, et al. Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary. J Pineal Res 2016; 60: 336-47.
21. Dash S, Xiao C, Morgantini C, Lewis GF. New insights into the regulation of chylomicron production. Annu Rev Nutr 2015; 35: 265-94.
22. Planas JM, Alfaras I, Colom H, Juan ME. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys 2012; 527: 67-73.
23. Celik Q, Celik E, Turkcuoglu I, et al. Surgical removal of endometrioma decreases the NF-kB1 (p50/105) and NF-kB p65 (Rel A) expression in the eutopic endometrium during the implantation window. Reprod Sci 2013; 20: 762-70.
Resveratrol (3,4',5-trihydroxy-trans-stilbene) or caffeic acid phenethyl ester supplementation prevents premature ovarian insufficiency due to chemotherapy

24. Myers M, Britt KL, Wreford NG, Ebling FJ, Kerr JB. Methods for quantifying follicular numbers within the mouse ovary. Reproduction 2004; 127: 569-80.
25. Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY) 2011; 3: 782-93.
26. Oktay K, Turan V, Titus S, Stobeski R, Liu L. BRCA mutations, DNA repair deficiency, and ovarian aging. Biol Reprod 2015; 93: 67.
27. Soleimani R, Heytens E, Oktay K. Enhancement of neangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One 2011; 6: e19475.
28. Wang D, Xiang DB, He YJ, et al. Effect of caffeic acid phenethyl ester on proliferation and apoptosis of colorectal cancer cells in vitro. World J Gastroenterol 2005; 11: 4008-12.
29. He YJ, Liu BH, Xiang DB, Qiao ZY, Fu T, He YH. Inhibitory effect of caffeic acid phenethyl ester on the growth of SW480 colorectal tumor cells involves beta-catenin associated signaling pathway down-regulation. World J Gastroenterol 2006; 12: 4981-5.
30. Lee KW, Chun KS, Lee JS, Kang KS, Surh YJ, Lee HI. Inhibition of cyclooxygenase-2 expression and restoration of gap junction intercellular communication in H-ras-transformed rat liver epithelial cells by caffeic acid phenethyl ester. Ann N Y Acad Sci 2004; 1030: 501-7.
31. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 2009; 486: 95-102.
32. Hussain AR, Al-Rasheed M, Manogaran PS, et al. Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006; 11: 245-54.
33. Juan ME, Wenzel U, Daniel H, Planas JM. Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem 2008; 56: 4813-8.
34. Cicero AFG, Ruscica M, Banach M. Resveratrol and cognitive decline: a clinician perspective. Arch Med Sci 2019; 15: 936-43.
35. Sergi C, Chiu B, Feulefack J, Shen F, Chiu B. Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials. Arch Med Sci Atheroscler Dis 2020; 5: e98-111.
36. Abeg F, Appelkvist E, Dallner G, Ernster L. Distribution and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys 1992; 295: 230-4.
37. Garrido-Maraver J, Cordero MD, Oropesa-Avila M, et al. Clinical applications of coenzyme Q10. Front Biosci 2014; 19: 619-33.
38. Kucinska M, Piotrowska H, Luccak MW, et al. Effects of hydroxylated Resveratrol analogs on oxidative stress and cancer cells death in human acute T cell leukemia cell line: prooxidative potential of hydroxylated Resveratrol analogs. Chem Biol Interact 2014; 209: 96-110.
39. Hussain AR, Uddin S, Bu R, et al. Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One 2011; 6: e24703.
40. Detampel B, Beck M, Krähenbühl S, Huwyler J. Drug interaction potential of resveratrol. Drug Metab Rev 2012; 44: 253-65.